Outpatient & home infusion
Rheumatology, GI, neurology and ID/OPAT infusion referrals
For infusion center operators and home infusion liaisons: find the rheumatologists, gastroenterologists, neurologists and infectious disease physicians billing infused biologics and IV therapies, by city or state, then save, export and route your calls.
State dashboard
Medicare Part B infusion administration and infused drugs, latest CMS year, read live from data.cms.gov.
| State | Estimated Medicare payment | Services | Billing providers (largest code) |
|---|---|---|---|
| Florida | $277,392,773 | 13,555,245 | 1,926 |
| Texas | $210,816,640 | 9,651,533 | 2,125 |
| California | $181,793,787 | 8,981,168 | 2,281 |
| New York | $117,054,131 | 5,594,527 | 1,605 |
| North Carolina | $112,785,330 | 6,439,772 | 926 |
| Illinois | $102,669,996 | 4,680,203 | 903 |
| Pennsylvania | $96,752,005 | 5,870,579 | 755 |
| South Carolina | $79,051,484 | 3,936,943 | 372 |
| Tennessee | $76,008,946 | 3,373,979 | 737 |
| Maryland | $75,247,163 | 3,791,009 | 564 |
| Virginia | $74,503,350 | 4,294,057 | 557 |
| New Jersey | $70,643,278 | 3,947,336 | 678 |
| Arizona | $66,082,886 | 3,888,697 | 551 |
| Ohio | $63,844,652 | 3,166,650 | 533 |
| Georgia | $57,645,643 | 3,078,432 | 624 |
| Alabama | $54,069,089 | 2,216,797 | 424 |
| Minnesota | $51,242,874 | 2,615,443 | 643 |
| Michigan | $48,157,651 | 2,369,505 | 451 |
| Missouri | $45,946,789 | 2,497,538 | 480 |
| Colorado | $44,639,703 | 2,469,009 | 424 |
| Oklahoma | $41,443,556 | 2,468,852 | 211 |
| Indiana | $37,519,754 | 1,938,267 | 351 |
| Washington | $34,437,593 | 2,069,009 | 531 |
| Arkansas | $30,086,081 | 1,431,854 | 213 |
| Massachusetts | $29,734,288 | 1,683,203 | 471 |
| Kentucky | $25,836,629 | 1,535,298 | 190 |
| Oregon | $25,563,272 | 1,494,175 | 304 |
| Wisconsin | $25,470,961 | 1,410,012 | 352 |
| Kansas | $24,921,211 | 1,335,578 | 171 |
| Iowa | $22,894,426 | 1,422,027 | 212 |
| Louisiana | $22,438,128 | 1,404,337 | 280 |
| Nebraska | $21,113,196 | 1,157,809 | 232 |
| Mississippi | $20,788,721 | 1,172,004 | 210 |
| Connecticut | $20,240,329 | 1,044,816 | 228 |
| Utah | $19,679,427 | 1,261,342 | 284 |
| Delaware | $15,142,118 | 806,899 | 60 |
| Nevada | $14,657,130 | 600,930 | 224 |
| Idaho | $11,573,260 | 778,553 | 75 |
| New Mexico | $10,697,199 | 529,015 | 128 |
| Maine | $7,763,004 | 509,527 | 71 |
| Alaska | $6,390,224 | 316,352 | 107 |
| New Hampshire | $6,305,433 | 327,431 | 51 |
| South Dakota | $5,470,726 | 347,033 | 82 |
| Montana | $4,427,489 | 374,487 | 72 |
| District of Columbia | $4,413,667 | 246,188 | 106 |
| Rhode Island | $4,350,333 | 248,208 | 55 |
| Wyoming | $3,915,792 | 188,117 | 54 |
| Vermont | $1,898,593 | 74,052 | 10 |
| North Dakota | $1,871,908 | 130,512 | 65 |
| West Virginia | $1,683,751 | 83,358 | 30 |
| Hawaii | $1,647,232 | 47,561 | 31 |
| Puerto Rico | $1,622,011 | 77,308 | 74 |
Top codes nationally
| Code | Description | Providers | Beneficiaries | Medicare payment |
|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug a | 4,252 | 25,596 | $554,799,816 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 5,592 | 11,319 | $334,780,924 |
| J3262 | Injection, tocilizumab, 1 mg | 3,709 | 14,162 | $263,325,890 |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g. | 3,799 | 9,296 | $211,887,800 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 7,437 | 27,763 | $211,838,920 |
| J2350 | Injection, ocrelizumab, 1 mg | 1,903 | 5,160 | $209,956,305 |
| J9312 | Injection, rituximab, 10 mg | 4,135 | 12,326 | $197,370,957 |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | 15,007 | 246,059 | $167,700,947 |
| J1300 | Injection, eculizumab, 10 mg | 638 | 344 | $101,338,806 |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or | 23,128 | 333,276 | $65,251,010 |
| J2323 | Injection, natalizumab, 1 mg | 1,243 | 1,501 | $58,768,027 |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e | 1,273 | 1,662 | $50,207,648 |
| 96415 | Administration of chemotherapy into vein, each additional hour | 12,428 | 101,035 | $13,674,994 |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each addit | 10,711 | 61,080 | $9,712,441 |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 1,227 | 1,265 | $2,652,278 |
“—” means CMS published no unsuppressed figure, not zero. Payment = CMS average Medicare payment × services. Original Medicare only; Medicare Advantage, Medicaid and commercial patients are not included.
Prescriber pathways show who bills infused drugs to Medicare, not who refers to your site. Drug amounts are per billing unit and are never compared across drugs. Facility, home infusion (DME/Part D), Medicare Advantage and commercial claims are outside this file. ID/OPAT prospect lists are useful, but most home IV antibiotics are billed outside Medicare Part B, so the Medicare dollar figures understate that market.
